🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 64 of 173

  1. US 10219492

    Compounds and methods for altering RSV replication rate

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10220001

    Active self-healing biomaterial system

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10221226

    LEDGF peptides and formulations thereof for treatment of degenerative disorders

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10221223

    Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10221222

    Dermaseptin-type and piscidin-type antimicrobial peptides

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10220002

    Controlled-release peptide compositions and uses thereof

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10214785

    Adeno-associated virus virions with variant capsid and methods of use thereof

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10214529

    Small molecules for the treatment of primary cancer and cancer metastasis

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10214536

    Amlexanox analogs

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10213430

    Nucleotide analogs

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10214566

    Mutant adeno-associated virus virions and methods of use thereof

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10214522

    Anti-alphavbeta1 integrin inhibitors and methods of use

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10214487

    Indole derivatives and methods of using the same

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10213478

    Compositions and methods for the treatment of fungal infections

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10206924

    Small molecule inhibitors of EGFR and PI3K

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10206897

    Creatine ester anti-inflammatory compounds and formulations

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10211414

    Phosphorescent tetradentate metal complexes having modified emission spectra

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10208103

    Use of HDL-related molecules to treat and prevent proinflammatory conditions

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10207013

    Gadolinium-based contrast agents for sensitive detection of Zn2+ with MRI

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10206986

    Annexin II variant compositions and methods

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10206953

    Ameliorating nervous systems disorders

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10206921

    Methods and compositions for treating a subject for central nervous system (CNS) injury

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10206904

    Licofelone derivatives and methods of use

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10206903

    Methods of treating muscular dystrophy

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10208012

    Compounds for treating inflammatory and hyperproliferative diseases

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10208059

    Heterocyclic modulators of HIF activity for treatment of disease

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10202657

    Adeno-associated virus virions with variant capsid and methods of use thereof

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10202397

    Anti-cancer compounds targeting Ral GTPases and methods of using the same

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10202618

    Method of treating type I diabetes using an AAV vector encoding uracortin 2

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10202584

    Red-shifted luciferase-luciferin pairs for enhanced bioluminescence

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10202428

    Compositions and methods for the delivery of oxygen

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10202340

    Glucosylceramide synthase inhibitors and therapeutic methods using the same

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10201613

    Method of creating hydrogels through oxime bond formation

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10201603

    Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10201554

    Esters of 2-deoxy-monosacharides with anti proliferative activity

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10201597

    Codon-optimized lentiviral vector for stem cell reprogramming

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10201282

    Genetically encoded infrared fluorescent protease reporters

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10201516

    Targeting K-Ras-mediated signaling pathways and malignancy by prostratin

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10196378

    Inhibitors of BCR-ABL mutants and use thereof

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10195297

    Iron garnet nanoparticles for cancer radiotherapy and chemotherapy

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10196458

    Anti-immunoglobulin E antibodies and methods of using thereof

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10196450

    Anti-OX40 antibodies and methods of using the same

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10195222

    Acyclic nucleoside phosphonate diesters

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10196356

    Mixed disulfide conjugates of thienopyridine compounds and uses thereof

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10190097

    Method and composition for inducing human pluripotent stem cells

    Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10189881

    MPS peptides and use thereof

    Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10188769

    Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same

    Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10188650

    Treatment of neurological disorders

    Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.